In a randomized withdrawal trial (Study 4), 783 patients were treated with ZEPBOUND for up to 36 weeks, and 335 of these patients were treated for up to 88 weeks [see Clinical Studies ]
[DOI] [PubMed] [Google Scholar] 14.Wenner M.M., Greaney J.L., Matthews E.L., McGinty S., Kaur J., Vongpatanasin W., Fadel P.J
According to the MHRA SmPC, Wegovy can cause a small mean increase in heart rate (approximately 24 beats per minute) with individual variability
The GCGR arm adds hepatic thermogenesis and lipolysis that tirzepatide does not generate
401 Bellini, R
First-line therapies, including metformin, sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and Glucagon-like peptide-1 (GLP-1) receptor agonists, are selected according to patient-specific risk factors